Patents by Inventor Thierry Mathieu

Thierry Mathieu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof
    Patent number: 12281170
    Abstract: Disclosed are senescent cell-associated antigen-binding domain and related antibodies and related chimeric antigen receptors. In addition, disclosed are DPP4-binding domains and related antibodies and related chimeric antigen receptors. Also disclosed are methods for treating, preventing or alleviating senescence-related diseases or disorders. Methods for depleting and/or killing senescent cells are also disclosed.
    Type: Grant
    Filed: June 23, 2023
    Date of Patent: April 22, 2025
    Assignee: StarkAge Therapeutics
    Inventors: Müge Ogrunc, Thierry Mathieu
  • SENESCENT CELL-ASSOCIATED ANTIGEN-BINDING DOMAINS, ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS COMPRISING THE SAME, AND USES THEREOF
    Publication number: 20240009242
    Abstract: Disclosed are senescent cell-associated antigen-binding domain and related antibodies and related chimeric antigen receptors. In addition, disclosed are DPP4-binding domains and related antibodies and related chimeric antigen receptors. Also disclosed are methods for treating, preventing or alleviating senescence-related diseases or disorders. Methods for depleting and/or killing senescent cells are also disclosed.
    Type: Application
    Filed: June 23, 2023
    Publication date: January 11, 2024
    Applicant: StarkAge Therapeutics
    Inventors: Müge OGRUNC, Thierry MATHIEU
  • Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof
    Patent number: 11723926
    Abstract: The invention relates to DPP4-binding domains, as well as antibodies and chimeric antigen receptors (CAR) comprising the same. Also disclosed are methods for treating, preventing or alleviating senescence-related diseases or disorders, or for depleting and/or killing senescent cells.
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: August 15, 2023
    Assignee: StarkAge Therapeutics
    Inventors: Müge Ogrunc, Thierry Mathieu
  • SENESCENT CELL-ASSOCIATED ANTIGEN-BINDING DOMAINS, ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS COMPRISING THE SAME, AND USES THEREOF
    Publication number: 20220193130
    Abstract: The invention relates to DPP4-binding domains, as well as antibodies and chimeric antigen receptors (CAR) comprising the same. Also disclosed are methods for treating, preventing or alleviating senescence-related diseases or disorders, or for depleting and/or killing senescent cells.
    Type: Application
    Filed: September 25, 2020
    Publication date: June 23, 2022
    Applicant: Stark Labs
    Inventors: Müge OGRUNC, Thierry MATHIEU
  • CHIMERIC ANTIGEN RECEPTORS AGAINST SENESCENT CELLS AND USES THEREOF
    Publication number: 20210093665
    Abstract: The invention relates to a chimeric antigen receptor (CAR) comprising directed to at least one senescent cell-associated antigen, preferably to DEP1 and/or DPP4; including bispecific CAR, bispecific antibodies, and isolated immune cell population expressing the same. It also relates to uses and methods for treating, preventing or alleviating senescence-related diseases or disorders, or for depleting and/or killing senescent cells.
    Type: Application
    Filed: September 27, 2019
    Publication date: April 1, 2021
    Applicant: Stark Labs
    Inventors: Müge Ogrunc, Thierry Mathieu